Sarepta Therapeutics, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect, as Class I directors to hold office until the 2028 Annual Meeting of Stockholders and until their successors are elected and qualified or their earlier death, resignation or removal, the following director nominees: Deirdre Connelly

Sarepta Therapeutics, Inc.’s own tally for this item (“Elect Director: Deirdre Connelly”): 53,419,881 for, 14,213,242 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company's board of directors as members of Class I for a term of two years.”
Support: 79% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 78 asset managers below reported 28,061,919 for, 8,980,479 against, 21,241 abstained, 74,235 not voted.

Showing the 25 largest of 78 asset managers. See all 78 in the interactive database.

Description as filed by funds: To elect, as Class I directors to hold office until the 2028 Annual Meeting of Stockholders and until their successors are elected and qualified or their earlier death, resignation or removal, the following director nominees: Douglas S. Ingram

Sarepta Therapeutics, Inc.’s own tally for this item (“Elect Director: Douglas S. Ingram”): 66,812,593 for, 827,973 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company's board of directors as members of Class I for a term of two years.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 78 asset managers below reported 36,979,788 for, 62,609 against, 21,241 abstained, 74,235 not voted.

Showing the 25 largest of 78 asset managers. See all 78 in the interactive database.

Description as filed by funds: To elect, as Class I directors to hold office until the 2028 Annual Meeting of Stockholders and until their successors are elected and qualified or their earlier death, resignation or removal, the following director nominees: Hans Wigzell, M.D., Ph.D.

Sarepta Therapeutics, Inc.’s own tally for this item (“Elect Director: Hans Wigzell, M.D., Ph.D.”): 56,984,756 for, 10,663,180 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company's board of directors as members of Class I for a term of two years.”
Support: 84% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 78 asset managers below reported 31,388,418 for, 5,653,980 against, 21,241 abstained, 74,235 not voted.

Showing the 25 largest of 78 asset managers. See all 78 in the interactive database.

Description as filed by funds: To elect, as Class I directors to hold office until the 2028 Annual Meeting of Stockholders and until their successors are elected and qualified or their earlier death, resignation or removal, the following director nominees: Kathryn J. Boor, Ph.D.

Sarepta Therapeutics, Inc.’s own tally for this item (“Elect Director: Kathryn J. Boor, Ph.D.”): 63,915,239 for, 3,722,626 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company's board of directors as members of Class I for a term of two years.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 78 asset managers below reported 36,286,992 for, 755,406 against, 21,241 abstained, 74,235 not voted.

Showing the 25 largest of 78 asset managers. See all 78 in the interactive database.

Description as filed by funds: To elect, as Class I directors to hold office until the 2028 Annual Meeting of Stockholders and until their successors are elected and qualified or their earlier death, resignation or removal, the following director nominees: Michael Chambers

Sarepta Therapeutics, Inc.’s own tally for this item (“Elect Director: Michael Chambers”): 65,892,431 for, 1,752,077 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company's board of directors as members of Class I for a term of two years.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 78 asset managers below reported 36,947,270 for, 95,127 against, 21,241 abstained, 74,235 not voted.

Showing the 25 largest of 78 asset managers. See all 78 in the interactive database.

Description as filed by funds: Approve the Company's 2026 Employee Stock Purchase Plan

Sarepta Therapeutics, Inc.’s own tally for this item (“4. Approval of the Company 's 2026 Employee Stock Purchase Plan”): 67,098,699 for, 532,525 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4: Approval of the Company 's 2026 Employee Stock Purchase Plan The stockholders approved the 2026 ESPP.”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Sarepta Therapeutics, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Approve Omnibus Stock Plan” (2 managers, 36,700 for, 74,235 not voted).

The 81 asset managers below reported 37,057,756 for, 21,246 against, 74,235 not voted.

Showing the 25 largest of 81 asset managers. See all 81 in the interactive database.

Description as filed by funds: Approve the Company's 2026 Equity Incentive Plan

Sarepta Therapeutics, Inc.’s own tally for this item (“3. Approval of the Company 's 2026 Equity Incentive Plan”): 63,233,193 for, 4,395,283 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: Approval of the Company 's 2026 Equity Incentive Plan The stockholders approved the 2026 Plan.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 79 asset managers below reported 35,470,391 for, 1,571,908 against.

Showing the 25 largest of 79 asset managers. See all 79 in the interactive database.

Description as filed by funds: Advisory vote to approve, on a non- binding basis, named executive officer compensation

Sarepta Therapeutics, Inc.’s own tally for this item (“2. Advisory Vote to Approve Named Executive Officer Compensation”): 45,185,398 for, 22,373,065 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: Advisory Vote to Approve Named Executive Officer Compensation The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers for 2025.”
Support: 67% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 79 managers: 28,695,923 for, 8,354,241 against, 21,242 abstained, 74,235 not voted. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 298 managers: 18,466,421 for, 16,233,561 against, 52,689 abstained, 2,376 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the current year ending December 31, 2026

Sarepta Therapeutics, Inc.’s own tally for this item (“5. Ratification of KPMG as the Company 's Independent Registered Public Accounting Firm”): 79,907,368 for, 2,110,136 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 5: Ratification of KPMG as the Company 's Independent Registered Public Accounting Firm The stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the current year ending December 31, 2026.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 78 asset managers below reported 37,016,366 for, 26,030 against, 21,242 abstained, 74,235 not voted.

Showing the 25 largest of 78 asset managers. See all 78 in the interactive database.